Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) EBT (2020 - 2025)

Historic EBT for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to -$3.7 million.

  • Ensysce Biosciences' EBT fell 68491.7% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 3939.96%. This contributed to the annual value of -$8.0 million for FY2024, which is 2756.07% up from last year.
  • Ensysce Biosciences' EBT amounted to -$3.7 million in Q3 2025, which was down 68491.7% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' EBT registered a high of $640683.0 during Q3 2024, and its lowest value of -$16.9 million during Q3 2021.
  • For the 5-year period, Ensysce Biosciences' EBT averaged around -$3.8 million, with its median value being -$2.7 million (2023).
  • Per our database at Business Quant, Ensysce Biosciences' EBT plummeted by 262352.48% in 2021 and then skyrocketed by 12359.82% in 2024.
  • Quarter analysis of 5 years shows Ensysce Biosciences' EBT stood at -$2.0 million in 2021, then plummeted by 209.65% to -$6.3 million in 2022, then surged by 44.02% to -$3.5 million in 2023, then fell by 2.48% to -$3.6 million in 2024, then fell by 4.47% to -$3.7 million in 2025.
  • Its EBT was -$3.7 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.0 million in Q1 2025.